Artificial Intelligence Development of New Drugs The Korea Pharmaceutical and Bio Association will hold an AI Pharma Korea conference to celebrate the 80th anniversary of its foundation
Sep 01, 2025
The Korea Pharmaceutical and Biological Association will hold the 'AI Pharma Korea Conference (hereinafter referred to as the conference")' to explore AI new drug development strategies and share the latest trends to mark the 80th anniversary of its foundation.
This conference, which marks its eighth anniversary this year, will be held at COEX in Samseong-dong, Seoul on September 25th and will be held under the theme of 'AX Pharmaceutical Bio: Value Creation Road, Future Road'. As one of the 80th anniversary projects of the association, it was organized as a representative event symbolizing the digital transformation of the domestic pharmaceutical bio industry.
Conference participation fees are free, and pre-registration is available on the official website of the Pharmaceutical Bio Association (KPBMA) or the AI New Drug Convergence Research Institute (CAIID) until September 18.
As a keynote lecture, Seok Cha-ok, a professor at Seoul National University, will present the topic of understanding the function of biomolecules using AI and overall design of therapeutic molecules. Then, Dr. Joseph Brown of the University of Toronto's Acceleration Consortium in Canada will give a special lecture on the development of new drugs through autonomous laboratories, and Tim Wahlberg (CPO) of CAS (an agency under the American Chemical Society) will give a special lecture on the data dilemma for the development of new AI drugs.
Chung Ho-hoon, a senior researcher at Yuhan Corporation, will lead the presentation in the first afternoon session under the theme of 「From AI-based drug creation to implementation」. Leader Park Yong-min presents examples of joint diagnosis and application of intermediary research of AI foundation models, while Professor Nam Ho-jung presents innovations in the discovery and development process of new drugs in the Generative AI era.
The second session will be hosted by Professor Hwang Dae-hee of Seoul National University under the theme of `The Fusion of AI and Biology.' Professor Yoon Tae-young of Seoul National University will present a high-speed search of the antibody sequence space using the SPID platform, and Shin Hyun-jin, director of the Mokam Life Sciences Research Institute, will present a new definition of a new drug R&D for the development of next-generation treatments.
In the third session, chaired by Yonsei University professor Jeong Jae-ho, there will be a place to share the new drug development strategy changed by the new technology. CEO of QNova Lee Jun-gu plans to present quantum computing technology, which has emerged as a hot topic in the development of new drugs, and CEO Kang Jae-woo of Eisen Science plans to present the use of domain-specific language models for precision medical and new drug development.
This conference, which marks its eighth anniversary this year, will be held at COEX in Samseong-dong, Seoul on September 25th and will be held under the theme of 'AX Pharmaceutical Bio: Value Creation Road, Future Road'. As one of the 80th anniversary projects of the association, it was organized as a representative event symbolizing the digital transformation of the domestic pharmaceutical bio industry.
Conference participation fees are free, and pre-registration is available on the official website of the Pharmaceutical Bio Association (KPBMA) or the AI New Drug Convergence Research Institute (CAIID) until September 18.
|
Chung Ho-hoon, a senior researcher at Yuhan Corporation, will lead the presentation in the first afternoon session under the theme of 「From AI-based drug creation to implementation」. Leader Park Yong-min presents examples of joint diagnosis and application of intermediary research of AI foundation models, while Professor Nam Ho-jung presents innovations in the discovery and development process of new drugs in the Generative AI era.
The second session will be hosted by Professor Hwang Dae-hee of Seoul National University under the theme of `The Fusion of AI and Biology.' Professor Yoon Tae-young of Seoul National University will present a high-speed search of the antibody sequence space using the SPID platform, and Shin Hyun-jin, director of the Mokam Life Sciences Research Institute, will present a new definition of a new drug R&D for the development of next-generation treatments.
In the third session, chaired by Yonsei University professor Jeong Jae-ho, there will be a place to share the new drug development strategy changed by the new technology. CEO of QNova Lee Jun-gu plans to present quantum computing technology, which has emerged as a hot topic in the development of new drugs, and CEO Kang Jae-woo of Eisen Science plans to present the use of domain-specific language models for precision medical and new drug development.
This article was translated by Naver AI translator.
